Keith W. Pratz, MD, on Gilteritinib With Induction and Consolidation Chemotherapies in AML

Posted: Tuesday, December 15, 2020

Keith W. Pratz, MD, of the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses results from his phase I study of gilteritinib in combination with induction and consolidation chemotherapies in patients with newly diagnosed acute myeloid leukemia, as well as the clinical implications, should subsequent trials confirm the efficacy and safety of gilteritinib in this setting.

---